0.61p+0.03 (+4.27%)28 Mar 2024, 13:21
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Provexis PLC Fundamentals

Company NameProvexis PLCLast Updated2024-03-28
IndustryDrug Manufacturers - Specialty & GenericSectorHealthcare
Shares in Issue2.218 bnMarket Cap£13.53 m
PE Ratio0.39Dividend per Share0
Dividend Yield0Dividend Cover0
EPS£-0.00EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio1.7072Cash Equity Ratio0.7068
Quick Ratio1.8282Current Ratio2.41
Price To Book Value13.1926ROCE0

Provexis PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Provexis PLC Company Financials

Assets202320222021
Tangible Assets000
Intangible Assets000
Investments000
Total Fixed Assets000
Stocks£327,797.00£85,808.00£60,576.00
Debtors£61,114.00£104,443.00£140,923.00
Cash & Equivalents£379,121.00£863,873.00£1.08 m
Other Assets000
Total Assets£845,992.00£1.13 m£1.29 m
Liabilities202320222021
Creditors within 1 year£188,337.00£157,909.00£150,681.00
Creditors after 1 year000
Other Liabilities000
Total Liabilities£188,337.00£157,909.00£150,681.00
Net assets£657,655.00£969,080.00£1.14 m
Equity202320222021
Called up share capital£2.22 m£2.21 m£2.21 m
Share Premium£18.70 m£18.68 m£18.68 m
Profit / Loss-£419,916.00-£299,132.00-£361,803.00
Other Equity£1.19 m£1.50 m£1.66 m
Preference & Minorities-£531,874.00-£529,999.00-£514,022.00
Total Capital Employed£657,655.00£969,080.00£1.14 m
Ratios202320222021
Debt Ratio000
Debt-to-Equity000
Assets / Equity1.70721.70721.7072
Cash / Equity0.70680.70680.7068
EPS£-0.00£-0.00£-0.00
Cash Flow202320222021
Cash from operating activities-£520,739.00-£213,615.00-£262,276.00
Cashflow before financing-£485,639.00-£213,615.00£786,124.00
Increase in Cash-£484,752.00-£213,537.00£786,075.00
Income202320222021
Turnover£389,916.00£426,168.00£505,330.00
Cost of sales£95,497.00£46,119.00£49,136.00
Gross Profit£294,419.00£380,049.00£456,194.00
Operating Profit-£420,927.00-£299,205.00-£361,916.00
Pre-Tax profit-£419,916.00-£299,132.00-£361,803.00

Provexis PLC Company Background

SectorHealthcare
ActivitiesProvexis PLC is a British food company. It is engaged in developing and licensing the Fruitflow, which is a patented, natural, breakthrough ingredient which helps with platelet aggregation. Fruitflow reduces the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can result in heart attack and stroke. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietarysupplement formats.
Latest Interim Date29 Dec 2023
Latest Fiscal Year End Date29 Sep 2023

Provexis PLC Directors

AppointedNamePosition
2008-09-01Mr. Krijn RietveldNon-Executive Director
2011-12-01Mr. Steven Neil MorrisonExecutive Director,Chief Operating Officer
2011-08-09Dr. Neville Clifford BainNon-Executive Director,Deputy Chairman
2014-08-29Mr. Stephen Nigel Moon Executive Director,Chief Executive Officer
2023-09-29Mr. Charles Dawson BuckNon-Executive Director,Chairman
2023-09-29Mr. Ian FordExecutive Director,CFO, CEO and Secretary
2011-08-09Mr. Stewart William Slade BSc,ACAExecutive Director,Finance Director and Company Secretary
2023-09-29Dr. Niamh Ann O'Kennedy Executive Director,Chief Scientific Officer

Provexis PLC Contact Details

Company NameProvexis PLC
AddressProspect House, 58 Queens Road, Reading, RG1 4RP
Telephone+44 7917670260
Websitehttps://www.provexis.com

Provexis PLC Advisors

SolicitorTLT LLP
RegistrarEquiniti Ltd.
Phone+44 1214157082
StockbrokerCenkos Securities
Phone+44 2073978900
Fax+44 2073978901
Financial PR AdviserHaggie Partners LLP
Phone+44 2075624444
Nominated AdviserCenkos Securities
Phone+44 2073978900
Fax+44 2073978901